West-Ward brings generic Aloxi to market
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has launched its generic Aloxi (palonosetron hydrochloriden injection). The drug is indicated to prevent acute nausea and vomiting associated with chemotherapy in adults. West-Ward’s generic Aloxi is the third generic of the product to launch in recent weeks.
"We are very pleased to add Palonosetron HCI Injection to our oncology portfolio," West-Ward injectables division CEO Riad Mechlauoui said. "The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business."
The drug, which the company is introducing in 0.25 mg/2 ml dosage strength, had a U.S. market size of $447 million for the 12 months ended January 2018.
"We are very pleased to add Palonosetron HCI Injection to our oncology portfolio," West-Ward injectables division CEO Riad Mechlauoui said. "The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business."
The drug, which the company is introducing in 0.25 mg/2 ml dosage strength, had a U.S. market size of $447 million for the 12 months ended January 2018.